Oxford, UK – 23 February 2015: Oxford BioMedica plc (LSE: OXB), (“OXB” or “the Company”) a leading gene and cell therapy company, today welcomed the Rt Hon Danny Alexander, Chief Secretary to the Treasury, to its laboratories on the Oxford Science Park.
During the visit, the Chief Secretary to the Treasury toured the Company’s process development lab, a facility dedicated to the development of robust and scalable manufacturing processes for gene and cell based therapies that have the potential to transform medicine.
In recognition of Oxford BioMedica’s leading position in gene and cell therapy, the Company was awarded a combination of grant and loan funding worth £7.1 million under the UK Government’s Advanced Manufacturing Supply Chain Initiative (AMSCI) in 2013. The funding was awarded to the Company to support Oxford BioMedica in becoming a world-leader and UK Centre of Excellence in the manufacture and supply chain of gene and cell based therapies.
Chief Secretary to the Treasury Danny Alexander said: "Our science base is one of the UK's most prized economic assets and I want us to remain a world-leader in science. That's why this government has committed £345m to the Advanced Manufacturing Supply Chain Initiative (AMSCI) to help strengthen and grow advanced manufacturing supply chains in the UK.
"It's great to visit Oxford BioMedica, which has invested AMSCI funding into becoming a world leader in the biopharmaceutical sector, creating new highly skilled local jobs that contribute to a stronger regional and national economy."
John Dawson, Chief Executive Officer of Oxford BioMedica, said: “Positive actions in life sciences by the government in recent years have helped to create a much more encouraging funding environment in the UK. Specific items such as R&D tax breaks and the Innovate UK fund have been enormously helpful and the AMSCI funding in particular has undoubtedly helped us to win a major contract with Novartis in the field of cell therapy last year.”
Notes to editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innovations, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.
For further information please contact
Oxford BioMedica plc
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Sarah MacLeod, Head of Communications
Tel: +44 (0)1865 783 000
Financial and corporate communications enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Olivia Manser/Laura Thornton
Tel: +44 (0)20 3709 5700